Streetbeat News

Regulatory

NVO

Novo Nordisk's weight-loss medication, Wegovy, will be priced at €301.91 for a four-week course in Germany. The drug will be launched in Germany by the end of this month. The company has urged doctors to restrict prescriptions to medically necessary cases. Challenges in production and high demand in the US have resulted in a slower European rollout of Wegovy than anticipated. Novo Nordisk has also filed lawsuits against three pharmacies for illegally selling products claiming to contain semaglutide, the active ingredient in its weight loss and diabetes drugs.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:40 pm

SPY

Federal Reserve's Goolsbee suggests that there is a method to control inflation without causing a recession. Recent weaker inflation data indicates that the Fed's efforts are showing progress.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:39 pm

BTCUSD

ETHUSD

XRPUSD

Cryptocurrency prices are on the rise with Bitcoin trading above $31,000 and Ethereum surpassing the $2,000 mark. XRP emerged as the top gainer over the past 24 hours following a partial victory against the SEC in a recent court ruling. The global crypto market cap rose to $1.25 trillion, recording a 24-hour gain of 5.8%.

Portfolio Pulse from Lisa Levin

July 14, 2023 | 1:38 pm

NTRB

NTRBW

Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has increased its existing credit line to $5 million to support the continued development and regulatory submission process for its patented lead product platform, AVERSA™ Fentanyl. The company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024. AVERSA™ Fentanyl, which combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva Drug Delivery’s FDA-approved transdermal fentanyl patch system, is estimated to reach peak annual US sales of $80M - $200M.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:21 pm

DUNE

Dune Acquisition Corporation has announced it will restate its previously issued audited financial statements due to a clerical error in the reported net income. The company expects no impact on its cash position, revenues, or liquidity.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 1:20 pm

CVM

CEL-SCI Corporation (NYSE:CVM) has concluded a meeting with the U.S. FDA regarding the approval of Multikine for the treatment of head and neck cancer. The FDA acknowledged the need for improved treatments and is open to collaboration with CEL-SCI. The company is also pursuing approval in Europe, the UK, and Canada, with commercialization possibly beginning in 2024 if Health Canada approves the submission. CEL-SCI's CEO highlighted the drug's potential benefits, including a 4-year median survival benefit and complete tumor elimination in some patients within 3 weeks.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:15 pm

BNED

Barnes & Noble Education is in the process of obtaining and implementing refinancing and other liquidity solutions, which will impact disclosures in Form 10-K. The company is considering various options including refinancing.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:06 pm

BNED

Barnes & Noble Education has filed a non-timely 10-K with the U.S. SEC. The company is also engaged in discussions with third parties to evaluate options to strengthen its liquidity and financial position.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:05 pm

CXAI

CXApp Inc. has added $5M to its balance sheet through warrant exercises. The company also added two Fortune 200 financial services customers last month, according to an SEC filing.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:02 pm

BZAMF

BZAM Ltd. (OTCQX:BZAMF) (CSE:BZAM) plans to purchase 630,000 class A shares of BZAM Cannabis Corp. from minority shareholders. The company will issue 255,000 common shares at an average price of $0.225 per share as consideration. The transaction, subject to regulatory approvals, will increase BZAM's stake in BCC from 57.6% to 71.2%.

Portfolio Pulse from Vuk Zdinjak

July 14, 2023 | 1:00 pm